Aicuris licences antisense RNA know-how from Hybridize Therapeutics
AiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1997 entries already.
Entries by Thomas Gabrielczyk
BioNTech collaborates with AGC Biologics
AGC Biologics supports BioNTech’s manufacturing of an Omicron-based vaccine with plasmids for in vitro transcription.
EU Council confirms European Scale-up Initiative
EU Members States agreed on Tuesday to launch the pan-European Scale-up Initiative, which is aimed to provide €10bn for late-state tech companies.
Protix raises €50m for expansion
Dutch insect protein specialist Protix has raised €50m for expansion and development from international investors and the ECBF.
Detect the Omicron variant of SARS-CoV-2 with Meridian Bioscience’s new antibody pair
A rapid antigen test provides a fast and reliable indication of the presence of the SARS-CoV-2 virus, the causative agent of Covid-19. A positive result of an antigen test is reliable, whereas a negative result does not completely rule out infection with the SARS-CoV-2 virus. The success of rapid tests is therefore limited by the sensitivity of the antibodies used.
Viennese Ribbon Biolabs closes €18m Series A financing
Ribbon Biolabs has cashed in €18m in Series A financing led by Hadean Ventures
mRNA specalist Ethris raises $26m in Series B financing
German mRNA and LNP specialist Ethris GmbH has closed a $26m Series B round led by Laureus Capital.
Evotec and Boehringer Ingelheim enter drug discovery deal
Evotec SE will use its PanOmics platform to validate and screen targets and drug candidates in ophtalmology for Boehringer Ingelheim.
BioNTech and Pfizer evaluate Omicron-specific vaccine
Pfizer Inc and BioNTech SE have started clinical safety testing of an Omikron-specific vaccine in healthy adults 18 through 55 years of age.
Cytovation AS kicks-off with $20m Series A financing
Norways immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater.